Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Other Non-Current Assets (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of Other Non-Current Assets data on record, last reported at $167000.0 in Q3 2025.

  • For Q3 2025, Other Non-Current Assets fell 27.07% year-over-year to $167000.0; the TTM value through Sep 2025 reached $167000.0, down 27.07%, while the annual FY2024 figure was $9.6 million, 734.4% up from the prior year.
  • Other Non-Current Assets reached $167000.0 in Q3 2025 per DNTH's latest filing, down from $9.2 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $9.6 million in Q4 2024 and bottomed at $60000.0 in Q3 2022.
  • Average Other Non-Current Assets over 4 years is $1.7 million, with a median of $229000.0 recorded in 2024.
  • Peak YoY movement for Other Non-Current Assets: tumbled 96.63% in 2023, then soared 13810.61% in 2025.
  • A 4-year view of Other Non-Current Assets shows it stood at $60000.0 in 2022, then skyrocketed by 1823.33% to $1.2 million in 2023, then skyrocketed by 734.4% to $9.6 million in 2024, then plummeted by 98.27% to $167000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $167000.0 in Q3 2025, $9.2 million in Q2 2025, and $231000.0 in Q1 2025.